Overview

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
Phase:
Phase 1
Details
Lead Sponsor:
Kessler Foundation
Collaborator:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam